Sign In
Buy ANNX
$5.39
+0.130 (+2.47%)
At Close: Jun 03, 2026
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
03:07am, Thursday, 04'th Jun 2026
Annexon NASDAQ: ANNX executives outlined a series of expected clinical and regulatory updates across the company's complement-focused pipeline during a session at the Jefferies Conference, highlightin
Annexon to Participate in Upcoming June Investor Conferences
08:00am, Wednesday, 27'th May 2026
BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 18'th May 2026
BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammato
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
04:06am, Thursday, 14'th May 2026
Annexon NASDAQ: ANNX President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcomi
Annexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
05:10pm, Wednesday, 13'th May 2026
Annexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
10:00am, Monday, 11'th May 2026
CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
04:01pm, Thursday, 07'th May 2026
Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA
Annexon to Present at the Bank of America Securities Health Care Conference 2026
08:00am, Wednesday, 06'th May 2026
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammato
Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing
03:31am, Friday, 17'th Apr 2026
Annexon (NASDAQ: ANNX) President and CEO Doug Love outlined a series of anticipated clinical and regulatory milestones during the 25th Annual Needham Healthcare Conference, describing 2026 as a "win y
Annexon (NASDAQ:ANNX) Shares Down 6.1% – Should You Sell?
04:10am, Sunday, 12'th Apr 2026
Shares of Annexon, Inc. (NASDAQ: ANNX - Get Free Report) traded down 6.1% on Friday. The company traded as low as $5.82 and last traded at $5.7650. 799,310 shares traded hands during trading, a declin
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
04:05pm, Wednesday, 08'th Apr 2026
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflamma
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?
10:55am, Wednesday, 01'st Apr 2026
The mean of analysts' price targets for Annexon (ANNX) points to a 165.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
04:01pm, Monday, 30'th Mar 2026
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 16'th Mar 2026
BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflamm
Annexon, Inc. (NASDAQ:ANNX) Receives $17.00 Average Target Price from Analysts
02:32am, Thursday, 05'th Mar 2026
Annexon, Inc. (NASDAQ: ANNX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the company, MarketBeat.com reports. One resear
